Atherosclerosis
Volume 206, Issue 2 , Pages 355-361 , October 2009

Statin prevents plaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation

  • Kae Nakamura

      Affiliations

    • Department of Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan
    • ,
  • Takeshi Sasaki

      Affiliations

    • Department of Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan
    • Department of Anatomy and Neuroscience, Hamamatsu University School of Medicine, 1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan
    • ,
  • Xian Wu Cheng

      Affiliations

    • Department of Cardiovascular Research Medicine, Nagoya University Graduate School of Medicine, Japan
    • Department of Cardiology, Yanbian University Hospital, 119 Juzijie, Yanji, Jilin Province 133000, China
    • ,
  • Akihisa Iguchi

      Affiliations

    • Department of Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan
    • ,
  • Kohji Sato

      Affiliations

    • Department of Anatomy and Neuroscience, Hamamatsu University School of Medicine, 1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan
    • ,
  • Masafumi Kuzuya

      Affiliations

    • Department of Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 52 744 2364; fax: +81 52 744 2371.

Received 14 January 2009 ,Revised 4 February 2009 ,Accepted 5 February 2009.

References 

  1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307
  2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.
  3. Sacks FM, Moyé LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 1998;97:1446–1452
  4. Simes RJ, Marschner IC, Hunt D, et al. LIPID Study Investigators, relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial. To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?. Circulation. 2002;105:1162–1169
  5. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res. 2001;49:281–287
  6. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. A randomized controlled trial. JAMA. 2001;285:1711–1718
  7. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  8. Rosenfeld ME, Polinsky P, Virmani R, et al. Advanced atherosclerotic lesions in the innominate artery of the apoE knockout mouse. Arterioscler Thromb Vasc Biol. 2000;20:2587–2592
  9. Calara F, Silvestre M, Casanada F, et al. Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. J Pathol. 2001;195:257–263
  10. Sasaki T, Kuzuya M, Nakamura K, et al. A simple method of plaque rupture induction in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:1304–1309
  11. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 2001;103:993–999
  12. Bea F, Blessing E, Bennett B, et al. Simvastatin promotes atherosclerotic plaque stability in ApoE-deficient mice independently of lipid lowering. Arterioscler Thromb Vasc Biol. 2002;22:1832–1837
  13. Williams JK, Sukhova GK, Herrington DM, et al. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol. 1998;31:684–691
  14. Johnson J, Carson K, Williams H, et al. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation. 2005;111:1422–1430
  15. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;105:868–873
  16. Sasaki T, Kuzuya M, Cheng XW, et al. A novel model of occlusive thrombus formation in mice. Lab Invest. 2004;84:1526–1532
  17. Kuzuya M, Nakamura K, Sasaki T, et al. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:1120–1125
  18. Jeziorska M, Woolley DE. Local neovascularization and cellular composition within vulnerable regions of atherosclerotic plaques of human carotid arteries. J Pathol. 1999;188:189–196
  19. Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25:2054–2061
  20. Langheinrich AC, Michniewicz A, Sedding DG, et al. Correlation of vasa vasorum neovascularization and plaque progression in aortas of apolipoprotein E−/−/low-density lipoprotein−/− double knockout mice. Arterioscler Thromb Vasc Biol. 2006;26:347–352
  21. Shiomi M, Fan J. Unstable coronary plaques and cardiac events in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits: questions and quandaries. Curr Opin Lipidol. 2008;19:631–636
  22. Wilson SH, Herrmann J, Lerman LO, et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation. 2002;105:415–418
  23. Brown DL, Hibbs MS, Kearney M, et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation. 1995;91:2125–2131
  24. Molloy KJ, Thompson MM, Jones JL, et al. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation. 2004;110:337–343
  25. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005;85:1–31
  26. Rodgers KJ, Watkins DJ, Miller AL, et al. Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2006;26:851–856
  27. Lutgens E, Lutgens SP, Faber BC, et al. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation. 2006;113:98–107
  28. Siegel-Axel DI, Runge H, Seipel L, et al. Effects of cerivastatin on human arterial smooth muscle cell growth and extracellular matrix expression at varying glucose and low-density lipoprotein levels. J Cardiovasc Pharmacol. 2003;41:422–433
  29. Riessen R, Axel DI, Fenchel M, et al. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells. Basic Res Cardiol. 1999;94:322–332
  30. Fabunmi RP, Sukhova GK, Sugiyama S, et al. Expression of TIMP-3 in human atheroma and regulation in lesion-associated cells: a potential protective mechanism in plaque stability. Circ Res. 1998;83:270–278
  31. Zaltsman AB, George SJ, Newby AC. Increased secretion of tissue inhibitors of metalloproteinases-1 and -2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity. Arterioscler Thromb Vasc Biol. 1999;19:1700–1707
  32. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23:769–775
  33. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte–endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol. 1999;19:2894–2900
  34. Sadeghi MM, Collinge M, Pardi R, et al. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J Immunol. 2000;165:2712–2718
  35. Pruefer D, Makowski J, Schnell M, et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation. 2002;106:2104–2110
  36. Nubel T, Dippold W, Kleinert H, et al. Statins inhibit high glucose-mediated neutrophil-endothelial cell adhesion through decreasing surface expression of endothelial adhesion molecules by stimulating production of endothelial nitric oxide. Microvasc Res. 2003;65:118–124
  37. Tiefenbacher CP, Kapitza J, Dietz V, et al. Reduction of myocardial infarct size by fluvastatin. Am J Physiol Heart Circ Physiol. 2003;285:H59–H64
  38. Yamakuchi M, Greer JJ, Cameron SJ, et al. HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res. 2005;96:1185–1192
  39. Rekhter MD. How to evaluate plaque vulnerability in animal models of atherosclerosis?. Cardiovasc Res. 2002;54:36–41
  40. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126–1131
  41. Eto M, Kozai T, Cosentino F, et al. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 2002;105:1756–1759
  42. Bickel C, Rupprecht HJ, Blankenberg S, et al. Influence of HMGCoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol. 2002;82:25–31

PII: S0021-9150(09)00105-1

doi: 10.1016/j.atherosclerosis.2009.02.014

Atherosclerosis
Volume 206, Issue 2 , Pages 355-361 , October 2009

Article Tools

* Image Usage & Resolution